Topline data were announced from a phase 3 trial evaluating ceralasertib plus Imfinzi in patients with locally advanced or metastatic NSCLC.
As the first immunotherapy option in this setting, the approval sets a new standard for resectable early-stage gastric and gastroesophageal junction (GEJ) cancers. As the first perioperative ...
Please provide your email address to receive an email when new articles are posted on . Durvalumab in the neoadjuvant and adjuvant setting conferred benefit in EFS and OS. Use of durvalumab did not ...
Adding Olaparib and Durvalumab Improved PFS in Patients Newly Diagnosed With Advanced Ovarian Cancer
Interim findings from the DUO-O trial could signal new options for women diagnosed with ovarian cancer at later stages who do not have a BRCA mutation. Patients newly diagnosed with advanced ovarian ...
Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window NEW YORK -- An ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to Healio Durvalumab appeared feasible and safe for ...
A regulatory decision is expected during the fourth quarter of 2025. The Food and Drug Administration (FDA) has granted Priority Review to durvalumab for the treatment of patients with resectable, ...
The appraisal committee considered evidence submitted by AstraZeneca, a review of this submission by the evidence review group (ERG), and responses from stakeholders. See the committee papers for full ...
Adding perioperative durvalumab (Imfinzi) to neoadjuvant chemotherapy significantly improved survival outcomes in cisplatin-eligible patients with muscle-invasive bladder cancer (MIBC), a phase III ...
The durvalumab arm showed a 32% decrease in the risk of disease progression, recurrence, not undergoing radical cystectomy, or death and a 25% reduction in the risk of death compared with the ...
The field of cancer treatment saw a variety of advancements in 2025, from new dedicated centers to approved treatments to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback